newsfilter
← Latest News
GlobeNewswire·

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

  • Harrow reaffirmed its full-year 2025 revenue guidance of $270 million to $280 million.
  • The company is on track to double the VEVYE sales force from approximately 50 to 100 US territories by Memorial Day 2026.
  • IHEEZO commercial expansion into the office-based setting is underway, targeting an addressable market exceeding 2.5 million annual procedures.
  • Harrow intends to double its surgical-based sales force supporting TRIESENCE in the coming months.
  • The OneHarrow initiative unifies branding & operations under a single organization to improve alignment & efficiency.
  • Patrick W. Sullivan was promoted to Chief Commercial Officer & received equity incentives tied to a $230 million quarterly branded revenue goal.
  • MELT-300 New Drug Application filings are on track for submission in the first half of 2027 following operational integration.
  • ImprimisRx settled regulatory matters with the California Board of Pharmacy, agreed to a $157,000 fine, & voluntarily exited the California market effective February 1, 2026.
  • Harrow will continue to serve the California market through its portfolio of branded products.